Market Leadership Claret Medical dominates the cerebral protection device market during TAVR procedures with approximately 97% market share in Europe and being first-to-market in the U.S., indicating strong brand recognition and a proven track record that can be leveraged to expand into new hospitals and healthcare systems.

Strategic Acquisition Being acquired by Boston Scientific for up to $270 million enhances resources, distribution channels, and credibility, providing an excellent opportunity to introduce and scale the SENTINEL device across a broader global customer base.

Innovative Portfolio The SENTINEL Cerebral Protection System is the only FDA-cleared device of its kind, offering a unique selling point; targeting hospitals and clinics performing TAVR procedures can lead to increased adoption by emphasizing safety and stroke reduction benefits.

Funding & Growth With $36 million in funding and a recent US market entry, there is potential for partnerships, pilot programs, and expansion into additional markets as the company scales its operations and capitalizes on increasing demand for neuroprotection solutions.

Target Customer Base Focusing sales efforts on high-volume TAVR centers, especially in Europe and the US, can accelerate sales growth, given the device's proven efficacy and the increasing adoption of minimally invasive cardiac procedures.